BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-602@pharmaconomics
DTSTAMP:20260707T034233Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:VTGN Phase 3 — fasiedienol (estimated date)
DESCRIPTION:Phase 3 trial results for fasiedienol in social anxiety disorder are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/vtgn-20260305.htm\n\nTrack it: https://www.pharmaconomics.com/e/602
URL:https://www.pharmaconomics.com/e/602
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VTGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR